Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02238496
Other study ID # AAAM3801
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date December 8, 2014
Est. completion date February 14, 2021

Study information

Verified date May 2023
Source Columbia University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test the effectiveness of a drug called temsirolimus in combination with a drug called perifosine in treating brain tumors that have continued to grow after previous treatment. Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain tumors. Perifosine is a pill that has not been approved by the FDA which blocks a messenger that tells cancer cells to grow. Research suggests that combined treatment with both drugs is better than either alone, and that it is reasonably safe.


Description:

Malignant gliomas are the most common primary brain tumors, and glioblastoma (GBM) is the most common subtype in adults, representing more than 50% of gliomas. Standard initial treatment for newly diagnosed GBM consists of maximal surgical resection followed by radiotherapy to the tumor bed and chemotherapy with an oral DNA alkylator, temozolomide. However, recurrence is nearly universal despite standard therapy. There is no standard treatment at recurrence. Median survival is about 15 months from diagnosis and 6 months from recurrence. Once patients develop tumor progression, conventional chemotherapy is generally ineffective.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date February 14, 2021
Est. primary completion date October 27, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed intracranial glioblastoma (GBM), including sub variants - At least 15 unstained slides or at least 1 tissue blocks must be collected from at least one prior surgery. - Received prior radiotherapy and prior temozolomide as treatment for the malignant glioma - Recovered from toxic effects of prior therapies and at least 2 weeks must have elapsed since any prior signaling pathway modulators; in general, at least 4 weeks must have elapsed from any other anticancer therapy - Able to undergo contrast enhanced magnetic resonance imaging (MRI) scans or CT scans - Shown unequivocal evidence for contrast enhancing tumor progression by MRI or CT in comparison to a prior scan - Age > or = 18 years - Karnofsky Performance Status > or = 70 - Life expectancy of > 8 weeks - Normal organ and marrow function, adequate liver function, and adequate renal function before starting therapy - Platelet count of at least 100,000/mm3 on at least 2 consecutive blood draws at least 1 week apart with results stable or trending upward - Normal coagulation - Cholesterol level < or = 350 mg/dl and triglycerides level < or = 400 mg/dl - Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation - Women of childbearing potential must have a negative beta-human chorionic gonadotropin (B-hCG) pregnancy test documented within 7 days prior to treatment - Women must agree not to breast feed - Ability to understand and the willingness to sign a written informed consent document - Ability to swallow tablets Group A (medical) specific inclusion criteria: - Fulfill all of the general inclusion criteria - At least 3 months between any prior brain radiotherapy and initiation of study therapy - MRI/CT must demonstrate measurable enhancing tumor of at least 1cm squared in cross-sectional area to allow assessment of radiographic response - On stable or decreasing dose of corticosteroids for a minimum of 5 days before the baseline MRI/CT - The baseline brain MRI/CT must be performed less than 15 days prior to initiation of study treatment. Otherwise it must be repeated Group B (surgical) specific inclusion criteria: - Fulfill all of the general inclusion criteria - Have cytoreductive surgery as part of their routine care for recurrent tumor - Have cytoreductive surgery as part of their routine care for recurrent tumor - A brain MRI/CT must be performed less than 15 days prior to initiation of study treatment. Otherwise it must be repeated Exclusion Criteria: - There is no limit on the number or type of prior chemotherapies except: 1. convection enhanced delivery, catheter based intra-tumoral treatment, or carmustine (BCNU)/Gliadel® wafers 2. stereotactic radiosurgery, or re-irradiation of any type 3. agent designed to inhibit mTOR or PI3K/AKT 4. direct Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptors (VEGFR) inhibitors - Smoking or plan to smoke tobacco or marijuana during study therapy - Plan to eat grapefruit or drink grapefruit juice during study therapy - Receiving any other investigational agents concurrently with study treatment - Taking hepatic Enzyme Inducing Anti-Epileptic Drug (EIAED) - Taking medications that are inducers or inhibitors of Cytochrome P450 3A4 (CYP3A4) for at least two weeks prior to study treatment - Uncontrolled intercurrent illness - HIV-positive patients on combination antiretroviral therapy - Other active concurrent malignancy - History of gout which can be exacerbated by perifosine - Known history of allergic reactions attributed to compounds of similar chemical or biologic composition to temsirolimus or perifosine - Therapeutic anticoagulation - History of hemorrhagic or ischemic stroke - Prior intratumoral bleeding must be evaluated with a non-contrast head CT to exclude acute blood prior to start of treatment

Study Design


Intervention

Procedure:
Cytoreductive surgery
Standard of care/routine cytoreductive glioma resection surgery. Arm B only.
Drug:
Perifosine
Perifosine is a pill that has not been approved by the FDA which blocks a messenger that tells cancer cells to grow.
Temsirolimus
Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain tumors.

Locations

Country Name City State
United States Columbia University Irving Medical Center New York New York
United States Memorial Sloan-Kettering Cancer Center New York New York

Sponsors (3)

Lead Sponsor Collaborator
Andrew B Lassman, MD AEterna Zentaris, Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical Benefit Rate Clinical Benefit Rate is defined as the radiographic response rate plus 6-month progression-free survival (PFS) rate. Up to 6 months from the start of treatment
Secondary Median Overall Survival Rate Overall survival will be calculated by using the interval between the date in which the first study drug administration took place (Arm A), and first day of study drug administration following surgery (Arm B), until the date of subject expiration. Up to 48 months from start of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05664243 - A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT02768389 - Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Early Phase 1
Recruiting NCT05635734 - Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT03679754 - Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 Phase 1
Completed NCT01250470 - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Phase 1
Terminated NCT03927222 - Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma Phase 2
Recruiting NCT03897491 - PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma Phase 2
Active, not recruiting NCT03587038 - OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma Phase 1
Completed NCT01922076 - Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Phase 1
Recruiting NCT04391062 - Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma Phase 2
Active, not recruiting NCT03661723 - Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Phase 2
Active, not recruiting NCT02655601 - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Phase 2
Completed NCT02206230 - Trial of Hypofractionated Radiation Therapy for Glioblastoma Phase 2
Completed NCT03493932 - Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade Phase 1
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Completed NCT03018288 - Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) Phase 2
Not yet recruiting NCT04552977 - A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma Phase 2
Withdrawn NCT03980249 - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells Early Phase 1
Terminated NCT02905643 - Discerning Pseudoprogression vs True Tumor Growth in GBMs